StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
5
Publishing Date
2022 - 06 - 13
6
2022 - 06 - 07
6
2022 - 05 - 24
6
2022 - 05 - 23
8
2022 - 04 - 06
6
2022 - 03 - 26
6
2022 - 03 - 07
7
2022 - 01 - 05
6
2022 - 01 - 04
8
2021 - 12 - 14
9
2021 - 12 - 13
6
2021 - 12 - 09
6
2021 - 12 - 06
10
2021 - 11 - 15
8
2021 - 10 - 25
7
2021 - 10 - 18
6
2021 - 09 - 29
8
2021 - 09 - 27
6
2021 - 09 - 16
6
2021 - 09 - 15
9
2021 - 08 - 31
6
2021 - 08 - 16
10
2021 - 08 - 05
6
2021 - 07 - 06
6
2021 - 06 - 28
9
2021 - 06 - 23
6
2021 - 06 - 17
6
2021 - 06 - 16
8
2021 - 06 - 11
9
2021 - 06 - 10
6
2021 - 06 - 08
8
2021 - 06 - 07
8
2021 - 06 - 04
8
2021 - 06 - 03
6
2021 - 06 - 01
7
2021 - 05 - 25
6
2021 - 05 - 19
8
2021 - 05 - 03
11
2021 - 04 - 23
7
2021 - 04 - 13
7
2021 - 04 - 12
9
2021 - 04 - 08
5
2021 - 03 - 23
6
2021 - 03 - 17
5
2021 - 03 - 16
9
2021 - 03 - 15
8
2021 - 03 - 10
6
2021 - 03 - 02
5
2021 - 02 - 25
7
2021 - 02 - 22
5
2021 - 02 - 12
5
2021 - 01 - 25
5
2021 - 01 - 19
5
2020 - 12 - 21
9
2020 - 12 - 17
7
2020 - 12 - 15
5
2020 - 12 - 10
9
2020 - 12 - 09
8
2020 - 12 - 07
10
2020 - 12 - 03
5
Sector
Health technology
5
Tags
5g
4
Acquisition
9
Alliances
5
Application
3
Authorized
4
Awards
3
Biopharma
9
Bioscience
5
Biotech
3
Biotech-bay
4
Brands
4
Cancer
8
Ceo
4
Clinical-trials-phase-ii
4
Collaboration
10
Commercialization
4
Communication
4
Communications
3
Conference
44
Contract
5
Covid
9
Covid-19
4
Diagnostic
4
Diagnostics
3
Disease
4
Drug
6
Energy
4
Europe
12
Events
15
Expansion
5
Financial results
6
Growth
18
Iot
7
Life science
5
Media
8
Merge
6
Mergers-and-acquisitions
4
Mobile
5
N/a
381
Offering
17
Ongoing
4
Partnership
7
People
4
Pharm-country
6
Phase 1
6
Phase 2
13
Phase 2b
6
Phase 3
5
Positive
12
Potential
7
Presentation
11
Research
24
Response
8
Results
20
System
5
Technology
14
Test
7
Therapy
5
Treatment
7
Trial
26
Entities
Bristol-myers squibb company
1
Syros pharmaceuticals, inc.
1
Tcr2 therapeutics inc.
1
Vistagen therapeutics, inc.
1
Zynerba pharmaceuticals, inc.
1
Symbols
BMY
1
SYRS
1
TCRR
1
VTGN
1
ZYNE
1
Exchanges
Nasdaq
4
Nyse
1
Crawled Date
2021 - 09 - 13
5
Crawled Time
10:00
1
11:00
1
12:00
3
Source
ir.vistagen.com
1
www.biospace.com
2
www.globenewswire.com
1
www.zynerba.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
publishing date :
2021 - 09 - 13
tags :
Phase 3
save search
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Published:
2021-09-13
(Crawled : 12:00)
- zynerba.com
ZYNE
|
$1.3
3.08%
860K
|
Health Technology
|
-70.92%
|
O:
0.0%
H:
1.9%
C:
-0.45%
phase 3
trial
syndros
zygel
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial
Published:
2021-09-13
(Crawled : 12:00)
- biospace.com/
BMY
|
$48.3
0.96%
-0.1%
11M
|
Health Technology
|
-23.55%
|
O:
0.54%
H:
0.06%
C:
-0.99%
therapy
phase 3
trial
nivolumab
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
Published:
2021-09-13
(Crawled : 12:00)
- biospace.com/
SYRS
|
$4.76
-6.85%
-7.35%
120K
|
Health Technology
|
0.79%
|
O:
0.0%
H:
6.9%
C:
3.16%
presentation
phase 1
trial
phase 2
phase 3
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
Published:
2021-09-13
(Crawled : 11:00)
- globenewswire.com
TCRR
4
|
$1.48
3.38%
3.9M
|
Health Technology
|
-91.82%
|
O:
1.71%
H:
3.42%
C:
-0.27%
solid tumors
ongoing
phase 1
results
trial
phase 2
phase 3
cel
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
Published:
2021-09-13
(Crawled : 10:00)
- ir.vistagen.com
VTGN
|
$4.69
0.43%
0.43%
200K
|
Health Technology
|
54.64%
|
O:
1.66%
H:
4.89%
C:
-1.63%
phase 3
social anxiety disorder
ph94
Gainers vs Losers
64%
36%
Top 10 Gainers
AGBA
|
News
|
$1.02
155.0%
57.94%
120M
|
Finance
ZCMD
|
$2.86
108.76%
52.1%
2.3M
|
Commercial Services
INVO
|
$1.555
104.6%
51.13%
5M
|
Health Technology
ISPC
|
$0.437
105.16%
49.53%
37M
|
Professional, Scientific, and T...
WLGS
|
News
|
$0.92
84.0%
45.65%
1.6M
|
OST
|
$0.499
21.38%
45.26%
1.9M
|
XPON
|
News
|
$3.1
60.62%
37.74%
17M
|
TIRX
|
$0.7
44.39%
30.74%
58M
|
BNTC
|
News
|
$6.92
44.17%
30.64%
3.5M
|
Health Technology
GGE
|
$0.035
19.86%
29.3%
64M
|
Your saved searches
Save your searches and get alerts when important news are released.